IOVA Stock Cash Flow Statements

Iovance Biotherapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Iovance Biotherapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-17	2012-12-31	2012-09-17	2011-09-17	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31

cash flows from operating activities
net income	-111,658,000	-116,163,000	-78,559,000	-83,541,000	-97,101,000	-112,976,000	-116,379,000	-113,760,000	-106,528,000	-107,370,000	-105,319,000	-99,618,000	-99,349,000	-91,607,000	-99,330,000	-86,122,000	-81,351,000	-75,449,000	-68,397,000	-58,571,000	-63,018,000	-69,595,000	-63,568,000	-49,487,000	-47,551,000	-36,950,000	-32,575,000	-33,830,000	-30,660,000	-26,515,000	-25,854,000	-22,149,000	-23,377,000	-20,684,000	-15,688,000	-18,759,000	-8,377,000	-7,617,450	-6,367,491	-5,298,059	-4,866,715	-2,259,514	-327,284	-5,772,679	-5,818,478	-10,959,740	-564,296	-741,922	-713,757
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	14,943,000	22,915,000	30,977,000	31,006,000	30,466,000	17,178,000	14,399,000	15,821,000	16,740,000	15,665,000	19,509,000	19,780,000	22,468,000	22,265,000	19,104,000	19,306,000	14,414,000	16,941,000	10,232,000	10,706,000	10,537,000	9,412,000	5,407,000	6,598,000	6,426,000	5,846,000	5,185,000	5,516,000	5,222,000	4,104,000	2,760,000	2,619,000	3,293,000	3,296,000	3,123,000
unrealized foreign exchange loss
amortization of intangible assets	5,698,000	5,406,000	5,546,000	5,537,000	5,486,000	4,633,000	3,910,000	4,006,000
amortization of right of use asset	2,877,000	2,870,000	3,166,000	2,582,000	2,393,000	2,296,000				2,933,000	2,893,000	2,748,000	3,003,000	3,181,000
depreciation and amortization of property and equipment	3,363,000	2,789,000	2,975,000	3,029,000	2,985,000	2,978,000	2,949,000	2,924,000
deferred tax expense
excess and obsolescence reserve
accretion of discounts and premiums on investments	-2,003,000	-2,146,000	-2,772,000	-2,655,000	-2,499,000	-2,335,000	-1,727,000	-1,023,000	123,000	-978,000
loss on asset disposals	0	44,000
changes in assets and liabilities:
prepaid expenses, other assets and long-term assets	-6,887,000	-3,251,000	-5,318,000	-2,472,000			-5,148,000	2,151,000	-2,834,000	-4,231,000	2,846,000	-2,315,000	1,054,000	-3,715,000
trade accounts receivable	11,000,000	-1,598,000	-13,572,000	-24,164,000	-31,370,000	-83,000
inventory	6,942,000	-13,970,000	-13,450,000	-10,873,000	-8,859,000	-6,735,000	-923,000
operating lease liabilities	-2,477,000	-3,113,000	-3,651,000	-2,945,000	-2,689,000	-2,789,000	-2,720,000	-2,813,000						690,000	-25,568,000	20,074,000	-1,728,000	1,340,000	-5,895,000	-1,840,000	-1,278,000	-2,461,000	-1,834,000	-1,663,000	-1,709,000	-942,000
accounts payable	893,000	2,052,000	-6,072,000	14,436,000	-10,390,000	-5,815,000	11,423,000	-9,766,000	146,000	3,025,000	1,556,000	4,262,000	2,169,000	-2,104,000	7,716,000	-5,690,000	4,965,000	-15,000	-12,132,000	16,264,000	672,000	-7,768,000	6,081,000	-3,326,000	5,369,000	4,582,000	-3,275,000	1,096,000	-1,553,000	5,239,000	-1,779,000	-839,000	1,521,000	1,466,000
accrued expenses and other liabilities	-281,000	2,250,000	4,084,000	12,701,000			9,405,000	15,931,000	3,492,000	-9,054,000	909,000	9,443,000	-9,891,000	-5,164,000	22,730,000	8,477,000	3,878,000	-14,401,000	15,854,000	-10,558,000	14,449,000	4,364,000	2,242,000	2,752,000	5,080,000	-3,346,000
net cash from operating activities	-67,447,000	-103,694,000	-73,296,000	-58,973,000	-98,429,000	-122,279,000	-83,970,000	-84,083,000	-93,952,000	-99,815,000	-77,671,000	-63,649,000	-77,635,000	-73,802,000	-53,849,000	-57,693,000	-54,008,000	-62,391,000	-62,692,000	-40,515,000	-36,635,000	-65,292,000	-53,822,000	-42,182,000	-33,795,000	-29,090,000	-31,549,000	-27,928,000	-23,923,000	-17,849,000	-20,964,000	-21,446,000	-17,496,000	-18,803,000	-12,159,000	-12,209,000	-6,579,000	-3,843,421	-4,499,930	-3,458,649	-3,314,930	-2,267,363	-1,200,511	-760,217	-1,649,502	-1,265,568	-564,475	-369,592	-113,320
capex	-669,000	280,000	-1,416,000	-17,000	-442,000	-3,488,000	-3,219,000	-3,638,000	-13,484,000	2,113,000	1,337,000	-728,000	-8,509,000	-6,540,000	-7,568,000	-8,942,000	-7,736,000	-13,963,000	-20,368,000	-20,693,000	-4,975,000	-5,323,000	-2,747,000	-1,699,000	-1,257,000	-1,092,000	-295,000	-463,000	-418,000	-34,000	58,000	-263,000	-25,000	-953,000	-740,000	-725,000	0	-72,867	-136,990	-782,143	0	-3,437	0	0	0	0	0	0	0
free cash flows	-68,116,000	-103,414,000	-74,712,000	-58,990,000	-98,871,000	-125,767,000	-87,189,000	-87,721,000	-107,436,000	-97,702,000	-76,334,000	-64,377,000	-86,144,000	-80,342,000	-61,417,000	-66,635,000	-61,744,000	-76,354,000	-83,060,000	-61,208,000	-41,610,000	-70,615,000	-56,569,000	-43,881,000	-35,052,000	-30,182,000	-31,844,000	-28,391,000	-24,341,000	-17,883,000	-20,906,000	-21,709,000	-17,521,000	-19,756,000	-12,899,000	-12,934,000	-6,579,000	-3,916,288	-4,636,920	-4,240,792	-3,314,930	-2,270,800	-1,200,511	-760,217	-1,649,502	-1,265,568	-564,475	-369,592	-113,320

cash flows from investing activities
maturities of investments	90,000,000	120,000,000	116,000,000	110,000,000	115,000,000	87,000,000	38,000,000	20,950,000	62,250,000	164,383,000	99,110,000	139,450,000	140,628,000	143,508,000	218,460,000	224,303,000	161,865,000	158,286,000
purchase of investments	-68,697,000	-97,922,000	-88,155,000	-156,513,000	-74,339,000	-141,762,000	-107,569,000	-93,010,000	0	-5,323,000	-95,627,000	-64,348,000	-40,289,000	-45,552,000	-141,554,000	-201,870,000	-311,414,000	-70,370,000
cash paid for acquisition, including contingent consideration, net of cash acquired			0
purchase of property and equipment	-7,461,000	-6,211,000	-4,168,000	-2,288,000	-442,000	-4,171,000	-3,529,000	-3,577,000	-9,520,000	-5,664,000	-3,022,000	-1,387,000	-4,576,000	-11,440,000	-7,568,000	-9,685,000	-9,616,000	-10,705,000	-23,335,000	-17,844,000	-4,975,000	-637,000	-3,426,000	-1,234,000	-1,433,000	-824,000	-295,000	-463,000	-418,000	-22,000	58,000	-263,000	-25,000	-798,000	-740,000	-725,000
net cash from (used) in investing activities
cash flows from financing activities
tax payments related to shares withheld for vested restricted stock units	-504,000	-5,644,000	-880,000	-6,277,000	-1,000,000	-4,701,000	-186,000	-379,000	-301,000	-1,929,000	0	0
proceeds from the issuance of common stock under employee stock purchase plan			1,390,000	0			1,139,000	0			1,073,000
proceeds from the issuance of common stock upon exercise of options	0	15,000	1,799,000	713,000	390,000	364,000	8,000	0			0	225,000	0	1,417,000				6,479,000	2,959,000	1,516,000	1,237,000	3,951,000	2,207,000	762,000	3,405,000	69,000	1,593,000	1,538,000	1,198,000	5,630,000	3,062,000	1,908,000	415,000	231,000	148,000		189,000
proceeds from the issuance of common stock	13,065,000	148,944,000	0	47,518,000	151,873,000	197,913,000	1,000	203,179,000	0	260,101,000					0	1,000	160,270,000	42,885,000	0	-350,000								0	-93,000	162,186,000							-1,000	162	0	68,307,838			0	250,000					700,000	0	365,000
net cash from financing activities	13,230,000	143,315,000	2,309,000	41,954,000	152,825,000	193,576,000	962,000	202,800,000	1,025,000	258,172,000				1,417,000			163,982,000	50,364,000	2,958,000	1,166,000			2,088,000	664,000	3,381,000	-2,000	239,345,000	12,022,000	3,360,000	169,580,000	2,899,000	56,054,000	-648,000	383,000	216,000	494,000	275,000	1,709,012	5,670,900	70,612,088	32,460,422	542,500	1,216,250	250,000	2,295,000			863,137	700,000	-18,137	360,017
effect of foreign exchange rate changes	739,000	508,000	-1,178,000	1,253,000	-125,000	-491,000
net increase in cash, cash equivalents and restricted cash	-39,636,000	55,996,000	-48,488,000	-64,567,000	94,490,000	-40,700,000	-152,832,000	37,710,000	-253,474,000	311,753,000	113,365,000	10,291,000	16,061,000	14,131,000
cash, cash equivalents and restricted cash beginning of period	0	122,053,000	0	0	0	181,318,000	0	0	0	238,161,000	0	0	0	84,313,000
cash, cash equivalents and restricted cash end of period	-39,636,000	178,049,000	-48,488,000	-64,567,000	94,490,000	140,618,000	-152,832,000	37,710,000	-253,474,000	549,914,000	113,365,000	10,291,000	16,061,000	98,444,000
supplemental disclosure of non-cash investing and financing activities:
net unrealized loss on investments	30,000	110,000
acquisition of property and equipment included in accounts payable and accrued expenses	6,792,000	6,491,000	2,752,000	2,271,000			310,000	-61,000	-3,964,000	7,777,000	4,359,000	659,000	-3,933,000	4,900,000
intangible asset and deferred tax liability arising from contingent consideration			0	-6,000,000	6,000,000	17,495,000
conversion of convertible preferred stock to common stock	0	1,000													2,000	0	0	-1,000					0				0	0
increase / (decrease) in lease liabilities due to obtaining/(reduction) in right-of-use assets from lease modifications	1,925,000	-1,429,000
unrealized foreign exchange gains		59,000	4,000	-93,000	10,000	-96,000
deferred tax benefit		-1,838,000	1,559,000	-1,521,000	-1,458,000	-1,408,000	-1,759,000	-1,243,000
net cash from investing activities		15,867,000	23,677,000	-48,801,000	40,219,000	-111,506,000		-79,014,000	-156,779,000	153,396,000				86,516,000	69,338,000			77,211,000	58,753,000	-52,955,000	-423,756,000	100,105,000	26,814,000	3,495,000	58,683,000	1,033,000	-206,382,000	-149,373,000	-30,502,000	-22,000	58,000	14,487,000	25,330,000	18,802,000	25,765,000	-16,557,000	9,737,000	-212,734			-1,426,016	-3,437			-3,455				0
accrued offering costs in accounts payable and accrued expenses						552,000
impairment of long-lived assets
gain on derecognition of lease assets and liabilities
vesting of restricted shares issued for services																																						465,130	637,425	450,445
fair value of net assets acquired							0	0
net unrealized gain on investments			-142,000				28,000	18,000
lease liabilities arising from obtaining right-of-use asset from new leases							0	0			0	0			0
lease liabilities arising from obtaining right-of-use asset from lease modifications			-19,333,000	203,000	0	11,297,000	-896,000	1,580,000	0	349,000	7,640,000	171,000	-180,000	7,673,000	0
accrued capitalized acquisition costs								-3,377,000
cash paid for acquisition, net of cash acquired							253,000	-3,377,000
net unrealized (loss) /gain on investments					20,000	-69,000
accrued expenses						-23,015,000																					1,229,000	1,674,000	872,000	-546,000	3,222,000	273,000	1,836,000	-776,000
contingent consideration paid for acquisition						-52,573,000
purchase of property and equipment included in accounts payable and accrued expenses						683,000
unrealized exchange gains							-106,000	357,000
loss on write-off of fixed assets											83,000	0	0	314,000
net cash from / (used in) investing activities											461,000	73,715,000
proceeds from the issuance of debt															0	0	0	1,000,000
effect of exchange rate changes							3,021,000	-1,993,000
amortization of right-of-use assets								2,945,000
inventories
depreciation and amortization										2,764,000	2,814,000	2,454,000	2,245,000	1,797,000	1,345,000	1,028,000	366,000	372,000	321,000	307,000	260,000	252,000	294,000	315,000	289,000	271,000	252,000	251,000	225,000	228,000	242,000	246,000	243,000	221,000	290,000	148,000			240,194	185,449	65,441	16,565	1,553	1,552	19,068
operating lease liabilities, net of tenant improvement allowance received										-2,569,000	-2,308,000	-536,000
net unrealized gain/(loss) on investments										776,000
accretion (amortization) of discounts and premiums on investments												133,000	454,000	541,000	836,000	1,315,000	1,796,000	2,066,000	1,506,000							-1,232,000
net cash (used in) / provided by financing activities												225,000
net unrealized (loss) on investments
proceeds from the issuance of common stock upon purchase of employee stock purchase plan
net unrealized gain on short-term investments														-1,742,000			-63,000	77,000				692,000
gain on settlement of dispute																							0	0	-1,000	-335,000
loss on disposal of assets																											0	0	0	9,000
cash, cash equivalents and restricted cash beginning of year
cash, cash equivalents and restricted cash end of year
net unrealized loss on short-term investments															-596,000
acquisition of property and equipment included in accounts payable and accrued expense
vesting of restricted stock units
non-cash lease expense																5,223,000
prepaid expenses, other assets, and long-term assets																3,834,000	1,029,000	7,130,000	-6,754,000	1,130,000	252,000	-1,316,000	-4,063,000	1,300,000	-2,107,000	1,592,000
right-of-use assets																-25,138,000	2,501,000	-2,660,000
proceeds from the issuance of common stock upon exercise of options and employee stock purchase plan																20,771,000
net cash provided in financing activities
net increase in cash, cash equivalents, and restricted cash																-24,173,000	-49,191,000	65,184,000	-981,000	-92,304,000
cash, cash equivalents, and restricted cash, beginning of period																0	0	72,854,000				19,419,000
cash, cash equivalents, and restricted cash, end of period																-24,173,000	-49,191,000	138,038,000				58,065,000
supplemental disclosure of non-cash operating, investing and financing activities:
acquisitions of property and equipment included in accounts payable and accrued expense																743,000	1,880,000	-3,258,000	2,967,000	-2,849,000
net cash used by investing activities
accrued offering costs in accrued expenses
noncash lease expense																		2,285,000	2,573,000	1,671,000	1,458,000	1,870,000	1,989,000	1,934,000	1,607,000	1,424,000
maturities of short-term investments																			318,108,000	141,815,000	103,013,000	113,665,000	94,021,000	157,478,000	172,060,000	91,042,000												11,900,000
purchase of short-term investments																			-236,020,000	-176,926,000	-521,794,000	-12,923,000	-63,781,000	-152,749,000	-111,944,000	-89,185,000	-247,087,000	-148,910,000										1,045,278
proceeds from the issuance of common stock upon exercise of warrants																											1,070,000	10,543,000	2,315,000	1,826,000	274,000	138,000	94,000	156,000	356,000	258,000	87,000	1,642,850			220,000
cash, cash equivalents, and restricted cash beginning of year
cash, cash equivalents, and restricted cash end of year
tax payments related to shares withheld for vested restricted stock awards																				0	-165,000	-118,000		-98,000	-24,000	-71,000	-42,000	-59,000	-60,000	-62,000
cash, cash equivalents, and restricted cash beginning of period																				0				0
cash, cash equivalents, and restricted cash end of period																				-92,304,000				-38,023,000
unrealized (loss) / gain on short-term investments
amortization of premiums on investments																					33,000	-50,000
unrealized gain on short-term investments																								-133,000	234,000	180,000					0	0	-2,000	-27,000	-134,000	85,000	10,000
net cash from / (used in) financing activities																						3,833,000
net increase / (decrease) in cash, cash equivalents and restricted cash																						38,646,000
acquisitions of property and equipment included in accounts payable and accrued expenses																						-4,686,000
proceeds from the issuance of preferred stock and common stock																															-388,000				0
supplemental disclosure of cash flow information:
cash paid for income taxes
interest paid
supplemental disclosure of noncash investing and financing activities:
acquisitions of property and equipment included in accounts payable																							679,000	-465,000	176,000	-268,000
accretion of discounts on investments																								-605,000
net decrease in cash, cash equivalents, and restricted cash
net (decrease) / increase in cash and cash equivalents																										-28,059,000
cash and cash equivalents, beginning of period																										82,152,000	0	0	0	145,373,000	0	0	0	106,717,000	0	19,945,000	-1,000	853	0	44,909,147	0	19,672,177			0	0	1,292,469	0	0	0	8,257
cash and cash equivalents, end of period																										54,093,000	1,414,000	-165,279,000	-51,065,000	297,082,000	-18,007,000	49,095,000	7,186,000	107,099,000	13,822,000	-8,327,000	3,432,000	-2,346,290	-98,724,153	111,280,443	27,719,476	17,943,877			642,043	-454,429	722,994	496,526	586,680	-102,536	311,799
offering costs under accounts payable and accrued expenses
prepaid expenses and other assets																											-1,421,000	-2,248,000	1,972,000	-368,000
net increase in cash and cash equivalents																													-51,065,000	151,709,000	-18,007,000	49,095,000	7,186,000	382,000						66,371,296	27,719,476	-1,728,300			642,043	-454,429	-569,475	496,526	586,680	-102,536	303,542
accretion and amortization of discounts and premiums on investments																												-387,000
unrealized loss on short-term investments																												-117,000
amortization of discount on investments
maturities of short- term investments																															0	14,750,000	25,355,000	19,600,000	26,505,000	26,278,000
acquisitions of property and equipment under accounts payable																														-12,000		0	0	-155,000
offering costs included in accounts payable																														-93,000
amortization of discount (premium) on investments																															0
other assets
purchase of short- term investments																																			0	-41,909,000
tax payments related to shares withheld for vested restricted stock
supplemental disclosures of cash flow information:
deemed dividend related to a beneficial conversion feature																																			0
prepaid expenses and other current assets																																-1,578,000	-1,021,000	-2,354,000	-1,768,000	-492,000					-24,993
amortization of premium on investments																																	9,000	28,000	-5,000
tax payments related to shares witheld for vested restricted stock awards																																	-1,157,000	-4,000	-288,000
net increase(decrease) in cash and cash equivalents																																			13,822,000
acquisitions of property, plant and equipment under accounts payable
accounts payable and accrued expenses																																				-1,682,000	-1,225,000	988,564	-44,521	248,957	656,302		327,882	372,176					9,715	-1,284	17,061
fair value of vested stock options																																					2,529,000	1,921,703	1,283,989	1,017,308	662,808
common stock issued for services																																									430,384	17,700	0	50,000	-2,426,548
liquidation (purchase) of money market funds
proceeds from the issuance of common stock upon exercise of stock options
proceeds from the issuance of preferred and common stock
interest
taxes
common stock issued to induce exchange transaction
common stock issued for lion transaction
common stock issued to directors
increase in money market funds																																					617,000	-13,085,145
purchases of property and computer equipment
proceeds from the issuance of convertible notes
proceeds from the issuance of preferred stock
common stock issued upon conversion of convertible notes
common stock issued upon conversion of accrued interest and penalty
depreciation
prepaid and other current assets
purchases of property and equipment																																						-72,867	-136,990	-782,143		-3,437
net decrease in cash and cash equivalents																																						-2,347,143					15,739	-510,217
supplement non-cash financing activities
prepaid expenses and deposits																																							-249,526	-62,749
common stock issued upon conversion of preferred stock
proceeds from the issuance of common stock upon conversion of warrants																																								2,304,250
cash paid during the period for:
income taxes
common stock issued to induce conversion of warrants
accounts payable to officers and former directors
accrued interest and penalty
settlement of accounts payable through issuance of common stock
amortization of discount on convertible notes
deposits
purchases of computer equipment and furniture
impairment of intangible asset
fair value of vested stock options and warrants																																										901,650	469,485	1,177,227	148,246
fair value of common stock and warrants accounted for as financing costs
fair value of vested warrants granted for services
private placement costs
change in fair value of derivative liabilities																																											-1,927,838	2,548,074
common stock issued to officer for services
fair value of common stock transferred to officer and director
write off of advances to related party
deposits, prepaid expenses and other assets																																										49,625	25,422	-20,186
accounts payable, accrued expenses and other current liabilities																																										-1,160,446
accrued compensation payable in shares of common stock																																										167,057
advances to related party																																													0	0	-50,000
proceeds from the issuance of secured promissory notes
proceeds from issuance of common stock upon conversion of warrants																																										542,500
due to director																																																	0
derivative liability recorded upon issuance of convertible
notes and warrants																																												182,081
derivative liability recorded as offering cost
common stock issued for intellectual property																																																0	0	0	217,408
forgiveness of debt by director, treated as contribution of capital
fair value of common stock issued with notes payable recorded as
a note discount
the accompanying notes are an integral part of these financial statements.
purchases of computer equipment
adjustments to reconcile net income to net cash used in
operating activities:
fair value of derivative liability recorded upon
issuance of warrants
common shares to be issued with 12% promissiory notes
fair value of common stock transferred to officer																																													0
and director
accrued expenses - national institute of health
property and equipment																																													-3,455
derivative liabilities
outstanding at december 31, 2011
granted
exercised
expired
outstanding at june 30, 2012
exercisable at june 30, 2012
issued
warrants:
risk-free interest rate
expected volatility
expected life
expected dividend yield
fair value of conversion feature
fair value of warrants
total fair value
item 2.
item 3.
item 4.
item 1.
item 1a.
item 5.
none.
item 6.
exhibit number
31.1
31.2
32.1
32.2
101.ins
101.sch
101.cal
101.def
101.lab
101.pre
xbrl interactive data files with detailed tagging will be filed by amendment to this quarterly report on form 10-q within 30 days of the filing date of this quarterly report on form 10-q, as permitted by rule 405(a)(ii) of regulation s-t.
genesis biopharma, inc.
august 14, 2012
bank overdraft																																												17,619
accrued expenses - national institutes of health																																												866,000
cash and cash equivalents, beginning of year																																												510,217
cash and cash equivalents, end of year
forgiveness of debt by director, treated as contribution
of capital
deposit																																															-2,500
prepaid expenses																																													2,500	5,292	-4,345	1,553	0
accounts payable and accrued liabilities																																													107,870	58,145	42,201
proceeds from convertible notes held in escrow account
derivative liability recorded upon issuance of convertible notes and attached warrants
derivative liability recorded as private placement cost																																													0
cash flows from operating activities:
loss on website																																																	0
change in fair value of derivative liability																																														398,556	-93,954
issuance of shares for services
changes in operating assets and liabilities:
cash flows from investing activities:
cash flows from financing activities:
proceeds from issuance of common stock																																														828,000	45,000
amortization of website
amortization of intellectual property license																																															18,117
fair value of vesting of stock options																																															40,302	68,857	43,818
website																																																	0
due from director
forgiveness of debt by director treated as contribution of capital
private placement cost.
gain on fair value of derivative liability																																																245,845
adjustment to reconcile net income to net cash from operating activities:
amortization																																																	174
fair value of derivative liability on issuance
supplemental disclosures of non-cash investing and financing activities:
taxes paid

We provide you with 20 years of cash flow statements for Iovance Biotherapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Iovance Biotherapeutics stock. Explore the full financial landscape of Iovance Biotherapeutics stock with our expertly curated income statements.

The information provided in this report about Iovance Biotherapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.